The long-term trend of the EPS is a vital number as it helps understand the future potential of DelMar Pharmaceuticals. It is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is unavialble, but historically the EPS change was 50.00% over the last twelve months. The long-term trend in EPS shows how well the management of DelMar Pharmaceuticals is adding value for shareholders.



DelMar Pharmaceuticals is part of the biotechnology industry and trades as part of the healthcare sector. The company CEO is Saiid Zarrabian. DelMar Pharmaceuticals Inc is a clinical stage drug development company. It is engaged in research and development of cancer indications.

Previous Intraday Performance:

The DMPI shares had a previous change of -7.41% which opened at 0.40 and closed at 0.38. It moved to an intraday high of 0.41 and a low of 0.37.

PR Newswire:  DelMar Pharmaceuticals Receives Nasdaq Listing Extension

Historical Performance:

Over the last five trading days, DMPI shares returned -4.38% and in the past 30 trading days it returned 4.51%. Over three months, it changed -36.25%. In one year it has changed -70.57% and within that year its 52-week high was 1.38 and its 52-week low was 0.31. DMPI stock is 23.39% above its 52 Week Low.

Our calculations result in a 200 day moving average of 0.64 and a 50 day moving average of 0.41. Right now, DMPI stock is trading -39.77% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

PR Newswire:  DelMar Pharmaceuticals Receives Nasdaq Listing Extension

Liquidity:

The company has a market cap of $8.6m with 22.6m shares outstanding and a float of 20.9m shares. Trading volume was 84,838 shares and has experienced an average volume of 81,263 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for DelMar Pharmaceuticals was 0.53 which ended on 30th of June 2018, which according to the previous close, that is a PE of 0.72. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.11.Historically, the PE high was 0.72 and the PE low was -0.70. DMPI stock has set a new PE low record!

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.09
06-30-2018:  -0.10
03-31-2018:  -0.13
12-31-2017:  -0.14



Indicators Also to Watch:

Based on the latest filings, there is 7.70% of insider ownership and 0.60% of institutional ownership.

I calculated the beta to be 1.71

SeekingAlpha:  Ekso Bionics up 35% on announcing JV in China

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is 641.69%, return on assets is 124.96% and price-to-book is 10.18.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here